News

Provecta is a small molecule, tumor-specific agent designed to treat melanoma, breast cancer, liver cancer and other potentially deadly cancers while sparing healthy tissue. Provectus expects to begin

The companies will use Genaissance’s HAP Technology for pharmacogenetic research to discover genetic markers that show individual responses to drugs. They will then aim to create diagnostic tests

The deal is particularly significant for Geron, which has spent large sums of money on its mission to develop drugs to combat cancer and other major illnesses. Under

GDNF has been shown to protect the neurons that produce dopamine that becomes depleted in Parkinson’s patients. GDNF has also been shown to have a beneficial role in

In tests done on female mice and mice heart cells, Dr Ellis Levin and his UCI colleagues found that estrogen triggers molecular activity that blocks cardiac hypertrophy, or

Intravenous delivery of IL-2 protein is approved as a treatment for metastatic melanoma, but frequently causes severe side effects. The novel treatment approach being studied in this trial

The study concentrated on the direct activation of the human checkpoint kinase 2 (Chk2), and showed that this caused the death of cancer cells independently of chemotherapy. Previously,

In the study, nightly use of Lunesta resulted in statistically significant improvement, compared with placebo, in patient-reported measures of sleep. Women treated with Lunesta reported fewer nocturnal awakenings

A key monoclonal antibody clinically shown to play an important role in fighting juvenile diabetes, anti-CD3 targets an antigen expressed on T lymphocytes, the cells of the immune